Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sutro Biopharma Inc (STRO)

Sutro Biopharma Inc (STRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 212,071
  • Shares Outstanding, K 8,514
  • Annual Sales, $ 62,040 K
  • Annual Income, $ -227,460 K
  • EBIT $ -186 M
  • EBITDA $ -188 M
  • 60-Month Beta 1.47
  • Price/Sales 1.95
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 110.06% (-1.63%)
  • Historical Volatility 76.04%
  • IV Percentile 2%
  • IV Rank 0.25%
  • IV High 1,186.13% on 11/04/25
  • IV Low 107.40% on 09/09/25
  • Expected Move (DTE 21) 3.57 (14.61%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 4
  • Volume Avg (30-Day) 32
  • Put/Call OI Ratio 7.64
  • Today's Open Interest 1,045
  • Open Int (30-Day) 1,383
  • Expected Range 20.86 to 28.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -2.43
  • Number of Estimates 5
  • High Estimate -1.23
  • Low Estimate -3.82
  • Prior Year -9.10
  • Growth Rate Est. (year over year) +73.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.65 +30.99%
on 03/03/26
26.54 -7.95%
on 03/09/26
+3.96 (+19.35%)
since 02/27/26
3-Month
10.15 +140.69%
on 01/05/26
26.54 -7.95%
on 03/09/26
+12.94 (+112.62%)
since 12/26/25
52-Week
5.23 +367.02%
on 04/17/25
26.54 -7.95%
on 03/09/26
+17.03 (+230.14%)
since 03/27/25

Most Recent Stories

More News
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned...

STRO : 24.43 (-1.93%)
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.

For growth-focused biotech investors, Vaxcyte is no longer just a science story.

PCVX : 53.16 (-2.83%)
STRO : 24.43 (-1.93%)
LZAGY : 61.2400 (-0.46%)
Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)
Sutro Biopharma Announces Participation at the 16th World ADC London Summit

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

– Initial clinical data expected mid-2026 – SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology...

STRO : 24.43 (-1.93%)
Sutro Biopharma Announces 1-for-10 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format...

STRO : 24.43 (-1.93%)

Business Summary

Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 26.06
2nd Resistance Point 25.58
1st Resistance Point 25.00
Last Price 24.43
1st Support Level 23.94
2nd Support Level 23.46
3rd Support Level 22.88

See More

52-Week High 26.54
Last Price 24.43
Fibonacci 61.8% 18.40
Fibonacci 50% 15.89
Fibonacci 38.2% 13.37
52-Week Low 5.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.